@APCC_Lugano 2024 is coming soon!!

Congrats to #latam KOLs Juan Pablo Sade Maite Bourlon Daniel Castellano for being part of panel members!!

Go check out our recent #MOASC2024 poster presentations. So honored to be working with such outstanding group of phyisicans. Thank you Oncology Tube Sumanta K. Pal, MD, FASCO for this opportunity to share our insights with the community

oncologytube.com/inspiring-inno…

Fin del Curso de Uro-oncología 2023-2024
Muchas felicidades Dr Mauricio Mora y Dra María Fernanda Rodríguez Mafer

Estamos orgullosos Yuly A. Remolina Maite Bourlon Dirección de Enseñanza del INCMNSZ INCMNSZ HEM ONC INCMNSZ INTERNAL MEDICINE Nayeli Adeline Thomas Flaig

Hallazgos sobre la eficacia y los resultados de CVRS de nivolumab más cabozantinib versus pembrolizumab más axitinib. DOI: 10.1016/j.euo.2023.01.012. Participación internacional del INCMNSZ Maite Bourlon

SOC Role of Frontline Nivolumab Plus Cabozantinib in Metastatic RCC Confirmed With Long-Term Efficacy Results Maite Bourlon ASCO #GU24 #oncology #MedTwitter #rcc
onclive.com/view/soc-role-…

💫🌟👏🔝 Kudos!! to 👩‍🎓Maite Bourlon for a crystal-clear presentation! at #GU24 ASCO
🔥 New #CheckMate9ER 55-Month Update!
📊 Nivolumab + Cabozantinib vs Sunitinib in aRCC
📈 Superior PFS, OS, ORR with N+C
🕒 Median PFS: 16.4 vs 8.4 months
⏳ Median OS: 46.5 vs 36.0 months
🎯

Always so useful to hear updates on pivotal P3 trials in #kidneycancer . Congrats to Maite Bourlon, Tannir & Grunwald on terrific talks updated #CM9ER , #CM214 & #CLEAR datasets. The #CM214 favorable risk data is particularly intriguing, but in general, the data today reinforces

Brillant presentation of CM-9ER by Maite Bourlon
Long-term follow-up shows success for Nivo+Cabo in aRCC treatment, hitting high notes in PFS, OS, and ORR compared to Sunitinib, especially for IMDC inter/poor group.
ASCO #GU24 OncoAlert UroToday.com Toni Choueiri, MD Emre Yekedüz

#GU24 Maite Bourlon given a brilliant talk (as usual) an updated data of CM9ER….